Launch of Mucodis® Rectal Gel

Quantum Pharma Plc

('Quantum' or the 'Group')

Launch of Mucodis® Rectal Gel

Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, is pleased to announce that Colonis, part of the Group's Niche Pharmaceuticals division, has launched its Mucodis® Rectal Gel for the prevention and treatment of rectal mucositis, a common side effect of chemotherapy and radiotherapy in cancer patients.

Mucositis is a condition characterised by pain and inflammation of the body's mucous membranes which line the digestive system from the mouth to the anus1. Of the circa 352,000 newly diagnosed cancer patients every year in the UK, 34% or approximately 118,000 patients have cancers situated in the lower abdominal or pelvic areas2. Estimates indicate that 90,000 people are living with chronic changes in lower GI function following radiotherapy or surgery from pelvic cancers3. These patients may be affected by rectal mucositis (Proctitis) which includes painful ulcers and bleeding in the patient's rectum and anus2.

Mucodis® Rectal Gel is the penultimate product to be launched in the initial Mucodis® range of 5 products which provides the NHS with prescribable products to address a number of the side effects associated with cancer treatments including mucositis, radiation-induced dermatitis, vulvovaginitis and proctitis. Colonis has been granted an exclusive distribution licence for these products for 5 years, with an option to extend beyond this initial period.

Andrew Scaife, Chief Executive of Quantum Pharma Plc, commented: "We are delighted to be able to provide this treatment to help aid proctitis, a painful and often incapacitating symptom associated with cancer treatment. We are excited by the potential that the Mucodis® range offers the NHS and patients as there is a clear unmet need for this type of relief and we are confident that our products will have a significant effect on improving patients' quality of life."

Footnotes

1. NHS Conditions, Mucositis (accessed June 2016)

 2. Cancer Research UK,http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-One (accessed June 2016)

3 Macmillan Cancer Support. Throwing light on the consequences of cancer and its treatment. Available from: http://www.macmillan.org.uk/Documents/AboutUs/Researchandevaluationreports/Throwingthelight report.pdf (Accessed April 2016)

- Ends -

For further information:

Notes to Editors

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials comprises four business units (Quantum Pharmaceutical, UL Medicines, NuPharm and Quantum Aseptics Services), which manufacture, procure and supply unlicensed medicines (specials) and special obtains. In response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment, the division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products. With an expansive portfolio of products, Quantum is a trusted partner to the majority of large retail pharmacy chains in the UK, as well as pharmaceutical wholesalers, hospitals, independent pharmacies and dispensing doctors.  The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products) which develop and commercialise niche pharmaceuticals. This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets through our Specials and Medication Adherence divisions to allow early identification of the market opportunity to take products from unlicensed (special) status to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

Medication Adherence comprises two business units (Biodose® and Biodose Services®) which provide products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies across the UK and provides the Group with exposure to the homecare and supported living sectors of the care pathway complementing the focus of the remainder of the Group.

For further information, please visit www.quantumpharmaplc.com.